See more : IGO Limited (IGO.AX) Income Statement Analysis – Financial Results
Complete financial analysis of enVVeno Medical Corporation (NVNO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of enVVeno Medical Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
- Shenzhen Kingsun Science & Technology Co.,Ltd (300235.SZ) Income Statement Analysis – Financial Results
- Zeon Corporation (ZEOOY) Income Statement Analysis – Financial Results
- China CIFCO Investment Co., Ltd (000996.SZ) Income Statement Analysis – Financial Results
- Saksoft Limited (SAKSOFT.BO) Income Statement Analysis – Financial Results
- Valuence Merger Corp. I (VMCAW) Income Statement Analysis – Financial Results
enVVeno Medical Corporation (NVNO)
About enVVeno Medical Corporation
enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 31.24K | 186.55K | 422.11K | 785.91K | 0.00 | 236.50K |
| Cost of Revenue | 546.00K | 525.00K | 452.91K | 383.97K | 0.00 | 0.00 | 419.66K | 810.29K | 125.42K | 132.32K |
| Gross Profit | -546.00K | -525.00K | -452.91K | -383.97K | 31.24K | 186.55K | 2.45K | -24.38K | -125.42K | 104.19K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.58% | -3.10% | 0.00% | 44.05% |
| Research & Development | 13.58M | 9.91M | 5.73M | 4.25M | 2.21M | 1.24M | 649.74K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.66M | 15.02M | 11.16M | 4.88M | 4.91M | 6.48M | 5.46M | 4.63M | 1.29M | 1.06M |
| Other Expenses | 0.00 | 0.00 | 33.27K | -215.91K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 25.24M | 24.93M | 16.89M | 9.14M | 7.12M | 7.72M | 6.11M | 4.63M | 1.29M | 1.06M |
| Cost & Expenses | 25.24M | 24.93M | 16.89M | 9.14M | 7.12M | 7.72M | 6.53M | 5.45M | 1.29M | 1.19M |
| Interest Income | 180.00K | 161.00K | 19.00K | 3.74K | 49.92K | 0.00 | 0.00 | 0.00 | 0.00 | 65.49K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.86M | 209.51K | 57.89K | 88.52K | 0.00 |
| Depreciation & Amortization | 220.00K | 525.00K | 452.91K | 383.97K | 396.67K | 133.42K | 139.21K | 151.17K | 125.42K | 134.13K |
| EBITDA | -25.02M | -24.51M | -16.75M | -8.75M | -6.96M | -6.05M | -5.73M | -5.38M | -1.16M | -818.53K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -21,252.47% | -3,967.65% | -1,818.04% | -573.60% | 0.00% | -346.10% |
| Operating Income | -25.24M | -24.93M | -16.89M | -9.14M | -7.68M | -7.85M | -6.10M | -4.66M | -1.29M | -952.66K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -24,566.50% | -4,210.51% | -1,445.89% | -592.84% | 0.00% | -402.82% |
| Total Other Income/Expenses | 1.72M | 263.00K | 364.68K | -360.00 | 49.92K | -5.19M | -1.69M | -929.08K | -88.35K | -65.49K |
| Income Before Tax | -23.52M | -24.67M | -16.53M | -9.14M | -7.63M | -13.04M | -7.79M | -5.59M | -1.38M | -1.02M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -24,406.74% | -6,991.46% | -1,845.83% | -711.05% | 0.00% | -430.51% |
| Income Tax Expense | 0.00 | -365.00K | -331.41K | -215.55K | 863.54K | 1.67M | 209.51K | -2.14M | 314.34K | 0.00 |
| Net Income | -23.52M | -24.30M | -16.20M | -8.92M | -7.63M | -13.04M | -7.79M | -3.39M | -1.60M | -1.02M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -24,406.74% | -6,991.46% | -1,845.83% | -431.03% | 0.00% | -430.51% |
| EPS | -1.91 | -2.16 | -1.87 | -6.91 | -12.10 | -34.83 | -20.10 | -7.72 | -3.66 | -4.26 |
| EPS Diluted | -1.91 | -2.16 | -1.87 | -6.91 | -12.10 | -34.83 | -20.10 | -7.72 | -3.66 | -4.24 |
| Weighted Avg Shares Out | 12.30M | 11.23M | 8.68M | 1.29M | 630.42K | 374.50K | 387.69K | 438.72K | 438.72K | 239.00K |
| Weighted Avg Shares Out (Dil) | 12.30M | 11.23M | 8.68M | 1.29M | 630.42K | 374.50K | 387.69K | 438.72K | 438.72K | 240.00K |
enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website
NVNO Completes Application for VenoValve's PMA, Shares Likely to Gain
enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium
enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval
Source: https://incomestatements.info
Category: Stock Reports